Bear Stearns Keeps 'Outperform' on OSI Pharma

Analyst Akhtar Samad says the company's plan to focus trials of its Tarceva drug on lung cancer is a positive move

Bear Stearns reiterates outperform on OSI Pharmaceuticals (OSIP ).

To continue reading this article you must be a Bloomberg Professional Service Subscriber.